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1. Introduction  
Bleeding disorders often present with different degrees of severity, ranging from very mild to 
very severe. Clinical presentation is not always correlated with the grade of the molecular 
defect and the disruption it causes to the gene/s in question. This is especially true for 
circulating coagulation factor deficiencies where even 1-2 % difference between levels of the 
deficient factor may result in significant variations in the clinical presentation. It is often the 
case that the residual level of factor does not serve as a reliable predictor of the clinical course 
in the particular patient. This is related to a number of reasons, including timing and accuracy 
of level measurement, antigenic properties/activity ratio of the deficient factor, nature of the 
molecular defect, presence of factors augmenting or alleviating the bleeding tendency (such as 
antibodies to the deficient factor, co-inherited prothrombotic risk factors, etc.). Therefore, 
prognostication of  disease course in young children and for the possibility of recurrence of the 
bleeding phenotype in the family could present quite a challenge to the genetic counselor. 
Nevertheless, this aspect of disease coping is very important to the family undergoing genetic 
counseling for haemophilia as it might influence their motivation for seeking adequate therapy 
and trying novel treatments, might induce overprotectiveness towards the affected child and 
most definitely could modify the family’s future reproductive plans (having one ill child and a 
grim perspective for the disease course usually does not encourage having more children). The 
ability to answer the questions of the parents about the prospective course of the disease with 
an acceptable degree of reliability is a crucial component of genetic counseling for haemophilia 
and requires gathering and processing a lot of information in order to produce a reliable image 
of what could be expected and what could be avoided.  
2. Factors that contribute to the haemophilic phenotype  
The avalanche stopping in its tracks a few feet above the cowering village  
behaves not only unnaturally but unethically. 
Vladimir Nabokov, Pnin (1957) 
 
Haemophilia A is a common (affecting 1:8000-1:10000 males) bleeding disorder caused by a 
deficiency of Factor VIII, a cofactor for the activated blood clotting factor IXa (Kazazian et al., 
1995). The latter is a serine protease, activating factor X in the coagulation cascade, which 
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ultimately leads to the conversion of prothrombin to thrombin and to formation of a fibrin clot. 
Deficiency of Factor IX produces haemophilia B, a more rarely encountered (approximately 
1:40000 males) bleeding disorder which is practically identical to haemophilia A in terms of 
clinical presentation as both factors act in the same biochemical pathway.  
It could be expected that the level of residual factor would be inversely proportional to the 
grade of clinical severity, i.e. the lower the level of residual factor, the more severe the 
bleeding tendency. The level of the deficient factor is calculated as a ratio of the coagulation 
capability of the patient’s plasma compared to a plasma pool of healthy males (taken as a 
100 % reference point). Generally, haemophilia in patients with levels of 0-1 % of the 
deficient factor is classified as severe, 2-5 % as moderate and 6-40 % as mild. Patients with 
undetectably low levels of the deficient factor or up to 1 % are at risk of bleeding after minor 
injury or even without apparent precipitating event (also called spontaneous bleeding).  
Bleeding tendency in severe haemophilia is usually noted early in life (around the age when 
the baby starts walking) or even in the immediate neonatal period because of 
cephalhaematoma after assisted delivery by means of forceps or vacuum extraction. Patients 
with levels within the 2-5 % range exhibit a heterogeneous spectrum of bleeding severity, 
ranging from indistinguishable from severe cases to mild, which becomes apparent only 
after serious challenge (e.g. dental manipulations). Patients in the mild category (6 % and 
upwards) are usually identified as haemophiliacs later in life (up to the fourth and fifth 
decade) and will usually bleed profusely only following a significant precipitating event 
(e.g. surgery, serious injury, etc.).  
Severe haemophilia accounts for about 50 % of all the cases that come to clinical attention, 
moderate cases are about 40 % and, respectively, mild haemophilia makes up for the 
remaining 10 %. It is believed that severe cases are overrepresented in the statistics at the 
expense of milder forms as patients with severe bleeding tendency are more likely to be 
entered into the relevant registries.  
It is more often than not that the patient presents with signs and symptoms of bleeding 
tendency of certain grade and subsequent clotting factor level measurements do not support 
the clinical findings. There are a number of reasons that might explain the discrepancy and 
each and every one of these must be checked and verified before a reliable assessment of 
disease severity and prognostication of the course of the disease could be made.  
2.1 Errors in determining the level of residual factor 
The first and foremost of the sources of errors in determination of clinical severity is 
inadequate timing of the coagulation factor level measurement. Often, families are 
motivated to visit the genetic counseling unit because of newly discovered pregnancy or 
because they are planning a pregnancy. It is often the case that the family does not actually 
know whether it is haemophilia A or haemophilia B that presents in their family and any 
laboratory data of a correctly taken blood sample from the index patient might not be 
immediately available. Thus, a sample taken from a haemophilic male ‘at random’ might 
produce spurious results. As a rule, errors of this type are biased towards measuring higher 
level of the deficient coagulation factor because of recent transfusion of plasma or blood 
clotting factor preparations. In our practice we had one haemophilic boy who repeatedly 
measured over 10 % of factor VIII when blood was taken for genetic analysis and some of it 
was tested for Factor VIII activity by two-stage assay. Since the patient had several 
spontaneous bleeding incidents on record, further investigation of the boy’s medical history 
was carried out. As it turned out, the boy liked competitive sports and his family regularly 
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requested a transfusion of factor VIII preparations at their local haemophilia center but 
chose not to share this information with the genetic counselor. Had the case not been 
thoroughly investigated, genetic analysis for most common defects causing severe 
haemophilia A would not have been chosen as first option in genetic analysis and the 
causative mutation would not have been discovered in time.  
There is also the question of whether the circulating residual clotting factor has adequate 
biochemical activity in vivo or not. Back in 1968, the antigenic properties of the deficient 
factor were also included as a component in the laboratory testing panel for haemophilia A 
and B (Roberts et al., 1968; Zimmermann & Edgington, 1973), broadening the classification 
of haemophilia forms to CRM (cross-reacting material) positive or CRM – negative. Later, 
Denson (1973) introduced the concept of FVIII:C (the biochemical activity of residual Factor 
VIII) versus FVIII:Ag (the antigenic properties of residual Factor VIII). Basically, it is the 
concept of presence of Factor VIII as an immunochemically recognizable protein but not as a 
cofactor activity. This might be the case when the underlying genetic defect in the Factor 
VIII gene produces a truncated or incorrectly folded protein. The majority of patients with 
severe haemophilia A have no detectable level of factor VIII protein in plasma (CRM-
negative) but there are about 5 % of all severe patients that are CRM-positive (though the 
amount of CRM is usually reduced). Therefore, the assessment of the residual factor VIII 
activity (FVIII: C) ought to be always coupled with measurement of the FVIII:Ag so as to 
avoid biased results because of detection of the FVIII protein in the plasma. It is very 
important that clear instructions are given about what measures should be taken to avoid 
errors in measurement of coagulation factor levels, as an incorrect result might cause delays 
in genetic analysis. The latter could be irreparable in cases when a high-risk pregnancy is 
involved.  
2.2 Antibodies to factor VIII 
About 10-50 % of patients with haemophilia who have been treated with plasma 
transfusions and/or preparations of Factor VIII or IX ultimately develop antibodies (also 
called inhibitors) to the deficient clotting factor  (de Biasi et al., 1994; Oldenburg et al., 2000; 
Ghosh & Shetty, 2009). This results in decreased therapeutic efficiency (with potentially fatal 
consequences for the patient if a major bleeding could not be managed properly) and 
increases the costs of treatment (as more units of the clotting factor are required to achieve 
the desired effect). It is generally believed that recombinant Factor VIII is more 
immunogenic that Factor VIII derived from pooled plasma (Aledort, 2004; Goudemand et 
al., 2006), but the results of a large cohort study carried out in 2007 (Gouw et al.) did not 
show an association between type of Factor VIII preparation and rate of development of 
antibodies to the clotting factor.  
Generally it is the patients with severe haemophilia that develop inhibitors to Factor VIII 
followed by patients with moderate disease (Schwaab et al., 1995; d’Oiron et al., 2008). This 
is only logical as the types of mutations which cause severe disease are more likely to 
produce CRM-negative haemophilia (hence, the exogenous Factor VIII protein is viewed as 
‘foreign’ by the immune system) or CRM-positive haemophilia with misfolded protein 
exposing unusual immunogenic epitopes (Oldenburg et al., 2002; Goodeve & Peake, 2003; 
Ragni et al., 2009).  
It is hard to predict whether the particular patient will develop antibodies to the deficient 
coagulation factor. The inhibitor phenotype is usually constituted via a fine interplay of 
genetic and non-genetic factors, though it is dependent on the type of the causative 
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mutation (Tuddenham & Oldenburg, 1995; Astermark, 2010). Generally, it is safe to advise 
parents of a patient with mild haemophilia that development of antibodies would be 
unlikely. This, however, would not  be the parent’s prime concern anyway, as their child 
most probably would not need regular transfusions of Factor VIII-containing preparations. 
In a case of severe or moderate haemophilia it is not acceptable to recite bluntly the risk 
percentages of antibody formation to the family as most often this will not register as a 
chance to have an uncomplicated therapy course but, rather, as a risk to develop an 
untreatable condition. It is more advisable to gently induce the parents to record the number 
of units transfused each time and the number of times when an unexpected bleeding has 
called for a transfusion out of schedule. This way a reliable estimate could be obtained of 
whether the same amount of units per kg body weight results in the same correction of the 
coagulation defect over time.  
In our practice we have observed only patients with severe disease develop anti-Factor VIII 
antibodies. In one case the genetic background was particularly interesting as there were 
two maternal first cousins with severe haemophilia A, one of which had very severe disease 
complicated by antibodies resulting in haemophilic arthropathy of both knee and ankle 
joints at the age of 11, while his cousin, aged 13, who apparently shared the same Factor 
VIII-gene disrupting mutation, only used Factor VIII-containing preparations at ‘on 
demand’ basis, typically less often than once in two months and had no major joint injury. 
At the time it was only possible to rule out Factor VIII inversions with breakpoints within 
the repeated intron 22 unit so the nature of the mutation remained unknown. Since the 
patients were first cousins and came from an ethnic group with a long-standing tradition of 
consanguineous marriages, there was a high chance that the two patients also shared 
common polymorphisms in other genes that play a role in the risk of inhibitor development. 
It is possible that the one cousin developed antibodies to Factor VIII because of more 
frequent encounters with this protein than the other cousin but the reason why one had 
more severe phenotype than the other was not identified.  
In cases when one haemophilic child with antibodies to the deficient clotting factor is 
already born, families are typically very reluctant to opt for another child as the presence of 
inhibitors seem to compromise the only possible therapy option. It is up to the genetic 
counselor to explain the risks of another case of antibody-complicated haemophilia to the 
family and to order additional tests if needed, such as HLA typing and/or IL-10 and TNF-
alpha polymorphism typing (Hay et al., 1997; Pavlova et al., 2009; Chaves at al., 2010). In 
one of our cases, there was a 21 g. w. pregnancy with a male foetus in a woman who has had 
already one son with severe haemophilia A complicated by high-titer antibodies to Factor 
VIII. DNA from the index patient was unavailable, so the nature of the mutation causing 
haemophilia in the family was impossible to identify. The most common mutations causing 
haemophilia A (inversions with a breakpoint in intron 22) were not identified either in 
peripheral blood of the mother (so that germinative mosaicism could not be ruled out) or in 
the foetus. In the process of genetic counseling it became clear that the family was accepting 
of the fact that they might have another boy with haemophilia but the issue that worried 
them the most was the risk of developing inhibitors in the course of treatment. Since the 
index patient and the foetus from the present pregnancy had different biological fathers, the 
risk that they shared the same set of genes was less that the 25 % expected by pure chance in 
full siblings, therefore the risk that they had inherited the same HLA class II type that could 
contribute to the risk of inhibitor development was less that the norm for siblings. The mother 
did not carry the TNF-alpha G308A polymorphism. Therefore, since the causative mutation 
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could not be determined (at least not in the very condensed timeframe imposed upon us by 
the advanced pregnancy) the family was presented with the options of carrying the pregnancy 
to term and risking having another child with haemophila A (about 30 % risk based on the 
premise that about 30 % of first cases of haemophilia A are born to noncarrier women) that 
might eventually develop inhibitors to Factor VIII, or, or selectively terminating the pregnancy 
and risking abortion of a healthy male foetus (70 %). After weighing the risks the family opted 
for carrying pregnancy to term and actually had a healthy boy. 
The incidence of antibody development in Bulgarian patients seems to be lower than usual 
(less than 10 %). We presume that this may be related to the practice of ‘on-demand’ 
treatment which was prevalent in Bulgaria until several years ago. With coagulation factor 
preparations getting more available to the patients, it could only be expected that the 
proportion of patients developing inhibitors to Factor VIII and Factor IX will reach the level 
reported elsewhere.  
2.3 Nature of the causative mutation  
A reasonable prediction of haemophilia phenotype and the course of the disease could be 
made based on the characteristics of the molecular defect. One must bear in mind, however, 
that the phenotype of the particular patient is not a direct function of the type of mutation 
but that additional genetic, epigenetic and environmental factors may play a role.  
The gene for Factor VIII is situated in the distal part of the long arm of the X chromosome, 
Xq28 (Gitschier et al., 1984). The gene spans 186 Mb genomic DNA and comprises 26 exons 
ranging from 64 to 3106 bp in length. The resulting Factor VIII protein has a complicated 
domain structure with numerous sites for interaction with other molecules. Therefore, 
almost every hit within the coding regions of the gene and sometimes in the noncoding 
sequences may result in haemophilia phenotype. Up to the present moment over 1000 
different mutations in factor VIII gene have been reported (Schwaab et al., 1991; Tuddenham 
et al., 1994, The Haemophila A Mutation Database,  
available from: http://hadb.org.uk/WebPages/PublicFiles/MutationSummary.htm, 
retrieved 14 May 2011). The mutation spectrum is heterogeneous with over 95 % of all 
mutations apart from the large gene rearrangements being single-nucleotide substitutions.  
As a rule, nonsense mutations result in severe, CRM-negative haemophilia. Missense 
mutations may produce a variable phenotype, depending on the site where the mutation 
has occurred. Generally, mutations in the sequence coding for the A2 domain of the Factor 
VIII gene result in CRM – positive haemophilia with varying severity (Wakabayashi & Fay, 
2008) as the A2 domain is responsible for the stability of the protein. Deletions of exons 
usually produces severe CRM-negative haemophilia A because of reading frame disruption 
except for deletion of exon 22 which results in an in-frame loss of 156 bp coding sequence 
(Youssouffian et al., 1987). and moderate haemophilia A. Deletions in the factor VIII gene 
are reported to be associated with increased tendency for inhibitor development because of 
incorrect protein folding resulting in exposure of immunogenic epitopes that are usually 
buried within the protein core (Youssouffian et al., 1987; Gouw et al., 2007, 2011). Specific 
mutation hotspots are 5-methylated cytosine residues which are readily deaminated to 
thymine (Youssoffian, 1986). These mutations usually result in introduction of premature 
stop codon (transition CGATGA) and, ultimately, in a truncated protein. The severity may 
vary depending on the site where the transition occurred but usually results in severe 
haemophilia with or without cross-reacting material as the truncated protein might be 
unstable in plasma (Reiner & Thompson, 1992).  
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2.3.1 Inversions with breakpoints in the 9.5 Kb repeated sequence in intron 22 of the 
factor VIII gene  
About 50 % of haemophilia A cases are severe. In about half of these 50 % (25 % of all cases) 
the causative mutation does not affect the coding sequences of the gene but, rather, 
rearranges the gene in a way that precludes normal splicing across the exon 22 – exon 23 
boundary of the gene (Naylor et al., 1992). Namely, this is a large inversion of the genomic 
portion containing exons 1-22 together as a unit which ultimately places them at 
considerable distance from exons 23-26. This is a randomly occurring event resulting from 
homologous recombination between inverted repeats located within the Factor VIII gene 
(intron 22) and outside the gene (Levinson et al., 1990, 1992).  
Intron 22 of the Factor VIII gene is remarkable in more than one aspect. It is a very large 
intron (32.4 Kb) and possesses a CpG island of its own. The latter serves as an origin of 
transcription for two transcripts internal to the Factor VIII gene, termed F8A and F8B, and 
orientated, respectively, one opposite (F8A) and one parallel (F8B) to the direction of 
transcription of Factor VIII (Levinson et al., 1990, 1992). The sequence coding for F8A is 
located within a 9.5 Kb fragment which constitutes the repeated unit. There may be three or, 
rarely, four or more repeated units per X chromosomе, one of which is always located inside 
intron 22 of the factor VIII gene and the others are extragenic, at distances of approximately 
300 and 400 Kb from the Factor VIII gene. The repeated units have a very high degree of 
homology (over 99.9 %). During meiosis, it is likely that homologous sequences may mispair 
with their homologues on the same chromosome and serve as breakpoints for 
recombination. As the repeats outside Factor VIII gene are orientated in the opposite 
direction to the intragenic copy, the resulting rearrangement is an inversion of the portion of 
the gene that contains exons 1-22 and relocation at considerable distance from the remaining 
part of the gene, namely, 300 Kb away for inversions that involve the proximal extragenic 
copy and 400 Kb away when recombination event involves the distal copy (Lakich et al., 
1993; Naylor et al., 1995). Thus, transcription from the Factor VIII promoter is possible but a 
full-length transcript cannot be obtained.  
These events occur exclusively during male meiosis, as the X chromosome does not pair 
with the Y chromosome except at the pseudoautosomal regions, providing ample 
opportunities for intrachromosomal homologous recombination. This means that the 
mutation occurs exclusively in the male germline (Becker et al., 1996; Arnheim & Calabrese, 
2009), resulting in carrier females born to a healthy mother and a father who carries a 
germline inversion mutation. Consequently, in the majority of cases where inversion is 
ultimately found, the haemophilic male who presents at the genetic counseling office is the 
first case in a family without history for bleeding diathesis. Nevertheless, it is very likely 
(over 90 %) for a woman who has had one haemophilic son with inversion to be a carrier 
(Rossiter et al., 1994), therefore the risk of her having another boy affected by haemophilia is 
close to 50 %, which equals the risk for proven carriers. Explaining to the family the origin of 
causative mutation and the associated risks could be challenging, especially in the light of 
the popular notion that women are solely responsible for transmission of haemophilia (as 
they give birth to affected sons). Generally, about 20-25 % of the females who have had a son 
with haemophilia have inherited the defective X chromosome from their healthy fathers 
(Haldane, 1935). Having more than one affected son does not confirm the carrier status of 
female as the de novo mutation rate in the female germline is estimated to be about 4 times 
lower than in the male germline (Becker et al.,1996) but is still significant, about 5 %. Of 
course, for the purposes of prenatal diagnosis 95 % risk of carriership is as good (in the case 
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of risk assessment, as bad) as 100 %, but nevertheless the genetic counselor must attempt to 
relieve the psychological burden of female carriership of haemophilia by emphasizing that 
in terms of de novo mutation occurrence it affects males and females alike, and that 
inversions occur in males several times more often than in females.  
When inversion is the case, the constitution of the disease phenotype could be fairly 
straightforward. As a rule, inversions of any type (involving distal, proximal and additional 
copies of the 9.5 Kb repeated unit) result in severe haemophilia with FVIII: C level below  
1%, unless another genetic component plays a role (e.g. co-inherited prothrombotic 
mutations). There are exceptions to the rule but they are fairly infrequent.  
It is very important to let parents know exactly what ‘severe’ means and what potential 
adverse outcomes there might be. A fairly common parental reaction is overprotectiveness. For 
chronically ill people of any age, and especially in children, overprotectiveness might actually 
be of a disadvantage as it might delay the development of various important skills. While 
parental concern is of prime importance in children with haemophilia, overprotectiveness may 
actually cause disregard for the major issue in severe haemophilia, namely, the proneness to 
spontaneous bleeding. Every day, dozens of small-scale bleeding events in the human body 
trigger the coagulation cascade. Some of them have the potential to develop into life-
threatening internal bleedings if coagulation is defective. In haemophiliacs with very low 
levels of circulating factor bleeding might be provoked by seemingly minor causes or without 
identifiable reason. Therefore, while overly concerned parents do not let their boy participate 
insporting activities or play with other children out of fear that it might spiral into a rough-
and-tumble that might induce bleeding; they might overlook the importance of checking 
regularly for signs and symptoms of bleeding. In our practice we had two very caring and 
protective mothers who, nevertheless, lost their sons following spontaneous bleeding incidents 
which were not recognized and treated properly because the mothers thought that since there 
was no preceding traumatic event, there was no cause to worry. It is vital to instill into the 
family the idea that bleeding must be ruled out first as a reason for any unusual event or 
complaint in a haemophilic male. 
There are other unhealthy psychological states in parents of chronically ill children, 
including children with haemophilia, that the genetic counselor must recognize and try to 
intervene. Among these, denial is prominent as it might lead to severe adverse 
consequences. Denial is often observed in families with young children that have just 
received diagnosis. Usually, denial in families with haemophilia manifests as unwillingness 
to accept the fact that the child would not ‘outgrow’ the disease and avoidance of routine 
therapy, such as refusing transfusion therapy with Factor VIII preparations and turning to 
purely symptomatic (cold pads, etc.) or alternative therapies, such as homeopathy, magnet 
therapy, etc. Unfortunately, parents in denial do not realize that they are paving their child’s 
way for major health trouble. It is the genetic counselor’s job to explain that the nature of the 
molecular defect causing the condition does not allow for the course of the disease to get 
any better so as to discourage any adverse health practices.  
The question of whether immunological response would be launched against the exogenous 
Factor VIII is more difficult to answer. In cases of inversions with breakpoints within the 
intron 22 repeated unit, the inversion disrupts the gene structure, precludes generation of a 
contiguous full-length transcript and results in undetectably low levels of Factor VIII in the 
patient’s plasma. Authors elsewhere have reported relatively high incidence of inhibitor 
formation in patients with inversion, up to 50 % (Oldenburg et al., 2002; Astermark et al., 
2005; Salviato et al., 2007). This is not unusual, as since there is no endogenous synthesis of a 
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certain protein, any encounter with it might trigger an immune reaction. Surprisingly, 
however, in our cohort of patients, none of the 25 patients with inversion with breakpoints 
within the repeated unit in intron 22 developed inhibitors to Factor VIII. This could be 
explained, however, by the prevailing practice of ‘on-demand’ treatment, that is, Factor VIII 
is administered only if there is an evidence of bleeding. Patients and their families should be 
informed about alternative approaches to combating the immune response to exogenous 
clotting factors, such as Factor VIIa, as this may generate and/or maintain the motivation 
for getting adequate treatment.  
2.3.2 Point mutations   
Generally, nonsense mutations cause premature arrest in mRNA translation, resulting in 
production of truncated protein. Since factor VIII is a large molecule with a multitude of 
sites responsible for interaction with other molecules, it is logical to assume that truncated 
protein variants would have limited, if any, ability to fulfill its functions. Therefore, 
nonsense mutations usually produce severe haemophilia, unless modulated by additional 
factors. For such patients, the basic assumptions for counseling families with severe 
haemophilia stand in place.  
Oftentimes non-inversion patients with factor VIII levels below 1 % develop inhibitors, 
which might be the phenotypic reflection of the immunogenicity of the truncated protein. 
We have had two patients with severe haemophilia and mutations in the 5’ – regulatory 
region of the Factor VIII gene which supposedly prevented transcription of the gene. 
Interestingly, they didn’t develop antibodies to exogenous Factor VIII, notwithstanding the 
fact that they have had over 20 years of treatment at the time of referral.  
As for missense mutations, it is very much up to the nature of the mutation in question 
whether the disease would be severe, moderate or mild and it is exactly with missense 
mutations where other factors (including genetic factors) play the most important role, as 
the modified protein may lose sites for interaction with other proteins or may, 
alternatively, gain such sites. As a rule, missense mutations cause CRM-positive 
haemophilia A with varying severity, depending on the mutation in question and the 
parts of the gene it affects. Recently, Wakabayashi et al. demonstrated that Factor VIII 
devoid of its C2 domain remains functional, at least in vitro, but is less stable 
(Wakabayashi et al., 2010). In our practice, we have had two (related) patients with exon 
24 missense mutation (the C2 domain) and with mild haemophilia A (40 %), supporting 
the notion of decreased stability of the protein.  
In moderate haemophilia, prognostication about the course of the disease in the particular 
patient could be rather difficult and could require a lot of cooperation from the patients and 
their families so as to carry out all necessary tests that could prompt as to how the defect in the 
Factor VIII gene clicks in place with other genetic and/or immunological factors that constitute 
the patient’s phenotype. For an example, we have had one adult patient with mild 
haemophilia according to Factor VIII levels (7 %) but prone since childhood to accidental 
haematuria without anaemia and/or haemolysis. Since haematuria is not very common even 
in severe haemophilia, further investigation was undertaken, resulting in identification of co-
inherited Factor XI deficiency, as described in Berg et al., (1994). The patient visited the genetic 
counseling unit so as to get an estimate of risks for transmitting his bleeding tendency to his 
children (specifically, his newborn daughter) and was, on the one hand, very relieved to know 
that haemophilia rarely is symptomatic in females, but, on the other, rather discontented to 
know that there might actually be increased risk of bleeding diathesis.  
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It could be hard to predict whether the patient would develop antibodies to exogenous 
Factor VIII in moderate and mild haemophilia. The rule of thumb is, however, that mild 
haemophilia usually is uneventful in regard to antibody production (in which the less 
frequent encounter with the exogenous factor preparations may play a role). As for 
moderate haemophilia, it is advisable that the parents keep a log of the amounts of 
preparations of clotting factor their child have had, the frequency of infusions and of any 
adverse events that may occur during or after transfusion so as not to miss the early signs of 
an impending immune conflict.  
2.4 Co-inheritance of prothrombotic mutations  
Carriership of molecular defects in other genes coding for proteins acting in the coagulation 
cascade may produce the so-called “thrombotic phenotype”, that is, increased tendency for 
thrombus formation. Usually, heterozygous carriership of such mutations (also called 
prothrombotic factors) in healthy people increases the risk of thromboembolism about 2-10 
times, depending on the mutation in question (Cumming et al., 1997; Hessner et al., 1999). 
Homozygous carriership may increase the risk for thrombotic incidents up to 50 - 100-fold 
(Souto et al., 1999; Ornstein & Cushman, 2003).  
The most commonly encountered prothrombotic mutations are the C677T in the 5, 10-
methylenetetrahydropholate reductase (MTHFR) gene (very common, prevalence of 
heterozygous carriership about 30-45 % in the general population), the G1691A substitution 
in factor V (Factor V Leiden) (between 2 and 6 % in the general population) and the 
G20210A mutation in the prothrombin gene (2-3 % in the general population) (Cumming et 
al., 1997; Antoniadi et al., 1999; den Heijer  et al., 2003). Generally, about half of the patients 
with thrombophilia carry either the Factor V Leiden mutation or the G20210 prothrombin 
mutation (Lillicrap, 1999). Carriership of both mutations in the heterozygous state 
additionally increases the risk of recurrent thrombosis about three times than the risk for 
carriers of each mutation alone (De Stefano et al., 1999).  
It is believed that the bleeding phenotype in patients with haemophilia might be modulated 
by concurrent inheritance of prothrombotic risk factors. Indeed, clinical practice often sees 
patients with clinical course less severe that could be expected from the residual levels of the 
deficient factor (Escuriola Ettinghausen et al., 2001; Tizzano et al., 2002; Franchini & Lippi, 
2010). In such patients the first symptomatic bleeding seems to occur at later age than in 
haemophilic counterparts without prothrombotic risk factors and the average amount of 
units per kg body weight used to manage the basic condition is lower. On the other hand, 
there are reports that co-inheritance of a mutation which causes increased tendency to bleed 
and a mutation that increases the proneness to thromboembolism may complicate the 
substitution therapy for haemophilia because of risk of deep venous thrombosis and/or 
central venous catheter (CVC)-thrombosis during transfusion of Factor VIII-containing 
preparations (Olcay et al., 1997; Kapur et al., 1997; Ettingshausen et al., 1999).  
Therefore, information about the patient’s status with regard to most common 
prothrombotic mutations may increase the degree of confidence when outlining the putative 
disease phenotype while, at the same time, advise caution when transfusing clotting factor  
preparations (especially concentrates) to a patient carrying a Factor VIII or factor IX 
mutation and a prothrombotic risk factor.  
2.4.1 Factor V leiden 
The process of haemostasis is controlled at numerous levels so as to avoid unmanageable 
intravasal coagulation. Normally, one of the basic mechanisms to control the clotting 
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process is proteolytic deactivation of the activated Factor V by activated protein C (APC), a 
serine protease with anticoagulant properties (Esmon, 1992).  
Factor V Leiden (FVL) is a common mutation in the factor V gene resulting in thrombophilia 
[Bertina et al., 1994]. The factor V protein product bears a high degree of homology to Factor 
VIII – both in domain structure and in function, as Factor V acts as a cofactor of factor Xa in 
the coagulation cascade (Kane & Davie, 1988). The Factor V gene, however, is an autosomal 
gene. In their homozygous state, mutation events disrupting the Factor V gene cause a rare 
bleeding diathesis called parahaemophilia or Owren’s disease (Owren, 1947).  
The Factor V Leiden mutation is a GA transition at nucleotide 1691 in exon 10 of the Factor 
V gene. At protein level this produces an Arg-to-Gln substitution which renders Factor V 
molecule uncleavable by APC, therefore resistant to its anticoagulant action. In healthy people 
this usually increases the risk for deep venous thromboses (DVTs) - mainly in the veins of the 
legs, but but also in the veins of the arms, the lungs, the abdomen, and the brain. In pregnant 
women, carriership of Factor V Leiden (and other prothrombotic mutations) is associated with 
multiplying (between 10 and 15-fold) the risk for of venous thromboembolism during 
pregnancy and late fetal loss (Koeleman et al., 1994; Gerhardt et al., 2000, Martinelli et al., 
2000). When co-inherited with haemophilia, FVL may modulate the bleeding phenotype 
and/or complicate the therapy with coagulation factor preparations.  
2.4.2 Prothrombin G20210A mutation 
The prothrombin-thrombin conversion is a key step in the coagulation cascade. The 
prothrombin G20210A variant (PT20210) is the second most common genetic mutation 
enhancing blood clotting. Again, it is autosomally inherited and is a transition GA but it 
has no effect on the coding sequence of the encoded protein, rather, it affects the 
polyadenylation site in the prothrombin gene (Poort et al., 1996), causing increased 
prothrombin levels in plasma. As with Factor V Leiden, the carriership of the PT20210 
mutation results in increased risk for thrombotic events (Chamouard et al., 1999; Franco et 
al., 2009), associated with the same concerns in patients with haemophilia who are on 
replacement therapy.  
2.4.3 MTHFR C677T mutation 
The human gene for 5,10-methylenetetrahydrofolate reductase  is an autosomal gene coding 
for an enzyme catalyzing the conversion of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate (Goyette et al., 1994), the latter being a substrate for methionine 
synthase catalyzing the homocysteine remethylation to methionine. The mutation is a CT 
transition in the protein coding regions of the gene, causing an alanine to valine substitution 
in exon 4 and reduced enzyme activity (Frosst et al., 1995). The resulting phenotype is of 
homocysteinemia associated with increased risk of vascular disease and thrombosis. 
The prevalence of the C677T mutation is very high in all ethnic groups. The heterozygous 
(CT) state is seen in 20 to 50 % in different populations while the TT homozygotes may 
amount up to 30 % (Wilcken et al., 2003), hence, it would certainly co-occur with 
haemophilia in a significant proportion of the patients.  
Since the prothrombotic mutations predispose to increased tendency for blood clotting, 
presumably co-inheritance of prothrombotic mutations and a mutation in the Factor VIII 
or Factor IX genes causing haemophilia might result in amelioration of the disease 
phenotype. This could present as later age of onset (age at which first symptomatic 
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bleeding occurs – for severe haemophilia typically around the age of 9-12 months when 
the baby learns to walk and bumps and falls are frequent) and/or fewer serious bleeding 
episodes and/or less episodes of spontaneous bleeding and/or less frequent rebleeding 
(rebleeding is a fairly frequent occurrence in haemophilia patients, as the clot, when 
finally formed, is friable and prone to breaking apart) and/or use of less units of the 
deficient clotting factor  (Lee et al., 2000).  
The flip side of the coin in co-inheritance of common prothrombotic mutations and 
haemophilia is the risk for complications of therapy, related to the fact that the presence of 
the prothrombotic mutation often increases the rate of thrombin formation (van 't Veer et al., 
1997). The several hundreds or thousands of coagulation factor units needed to stabilize the 
patient’s haemostasis are often transfused rapidly, within one minute or even faster. The 
general recommendation is that any blood clotting factor preparation should be infused 
slowly with no more than 2 ml of solution infused per minute so as to avoid complications, 
but the unfortunate practice shows that in at-home treatment schemes and sometimes even 
in clinical settings the whole amount of 3-10 ml of reconstituted coagulation factor is infused 
too rapidly - within a couple of dozens of seconds, out of desire to achieve results faster. 
Thus, in haemophilic patients with prothrombotic mutations, the therapy with clotting 
factors may provoke thromboembolic events – with disastrous consequences for the patient. 
There have been reports of cerebral and cardiac thrombotic incidents associated with Factor 
V Leiden carriership in haemophilic patients (Olcay et al., 1997, Iannaccaro et al., 2005). 
Therefore, it is important to screen haemophilic patients for prothrombotic mutations – with 
regard to possible disease phenotype modulation as well as in relation to possible 
modifications of therapy, in order to prevent adverse events.  
Our experience to date shows that the three most common prothrombotic mutations (Factor 
V Leiden, PT20210 and MTHFR C677T) seem not to modulate the disease phenotype in all  
patients with haemophilia. Apparently, Bulgarian patients with severe haemophilia gain no 
benefits from neither of the co-inherited prothrombotic mutations, as all identified carriers 
exhibit the classical ‘severe’ phenotype, with frequent spontaneous bleedings and age of 
onset before the first year of life. There was no difference between the number of 
haemorrhagic episodes and/or the units of Factor VIII used per kg body weight per year 
between patients carrying prothrombotic mutations and patients who did not have 
additional mutations affecting components of blood coagulation cascade. It seems that the 
carriership of prothrombotic mutations does not contribute to the phenotype constitution in 
the local haemophilic population.  
It could be challenging to predict whether and when in the course of therapy a haemophilic 
patient might experience a thrombotic event, especially if the patient is very young at the 
time of referral. Considering the risks that are associated with replacement therapy, 
however, it is advisable that the families are warned about the possibility of 
thromboembolism during or after clotting factor application. Until proven otherwise, 
identification of a prothrombotic mutation in a patient with severe haemophilia is another 
factor that should be considered as an additional potential risk source when defining the 
risks associated with therapy. It is vital to teach the family members that in case of signs of 
impending haemorrhage quick action is advisable but that speed should be made in 
contacting the attending physician (if deemed necessary), obtaining the clotting factor 
preparation (if it is not immediately available) and preparing it for use but not in the process 
of infusion itself as it may lead to severe adverse events. Patients with non-00 AB0 blood 
group should constitute a group of special concern for such events as it has been repeatedly 
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demonstrated that blood group different from 00 additionally increases the risk for 
thrombosis about 5-fold (Fontcuberta et al., 2008; Jukic et al., 2009).  
In our practice we have observed patients with Haemophilia A and unusually mild bleeding 
phenotype discordant with the level of residual factor - 0-1 % as determined by at least two 
independent tests. Namely, the patients were seldom treated with factor VIII - less than  six  
times per year - usually as a preventative measure before surgery or dental procedures. 
Bleeding incidents were usually preceded by a precipitating event and managed effectively by 
bandaging, cold applications and rest. Only one patient (55 years of age at time of referral) had 
unilateral haemophilic arthropathy of the knee which did not interfere significantly with 
everyday activities. Interestingly, in about half of these patients the causative mutation of the 
factor VIII gene was the large inversion involving the repeated unit in intron 22, therefore, the 
milder phenotype could not be explained by Factor VIII-gene related reasons (in-frame 
deletions, ‘leaky’ mutations, etc). None of these patients had a Factor V Leiden or PTG20210 
mutation and the prevalence of MTHFR C677T in this group did not differ significantly from 
the basic values for European Caucasoid populations (30 %). It is possible that the milder 
phenotype might be attributed to carriership of MTHFR C677T but, as of now, until proven 
otherwise, carriership of any prothrombotic mutation must be considered to be associated 
with increased risk for adverse effects of the replacement therapy. Families should be advised 
to keep a log of the infused units and the frequency of infusions of clotting factor-containing 
preparations so as to illuminate any positive connection between co-carriership of 
prothrombotic mutations and milder course in haemophilia.  
Women carriers of prothrombotic mutations are at risk of preeclampsia and fetal loss. 
Female carriers of haemophilia and prothrombotic mutations who are pregnant or planning 
to become pregnant should be informed about the risks associated with the pregnancy (risks 
for having a haemophilic boy stemming from the carriership of haemophilia-producing 
mutation and risks for both the mother and the foetus because of the carriership of a 
prothrombotic mutation) and referred for intensive pregnancy monitoring so as to avoid 
complications. Again, contribution of other risk-modifying factors such as AB0 blood group, 
smoking, etc. should be evaluated.  
2.5 Infections transmitted by transfusion of blood or blood products  
The risk of infection with any of the common blood-transmitted diseases is significant for 
patients receiving regular transfusions of plasma, blood and blood products. Even 
considering the improvements in the sensitivity of the methods screening for infectious 
disease transmitted by blood and blood products, there still remains a risk for infection 
which is proportional to the number of occasions in which the patient has been exposed to 
blood, plasma, cryoprecipitate, etc. Basically all Bulgarian patients over 20 years of age are 
chronically HbsAg – positive and a significant proportion of them test as HCV-positive. 
Thankfully, the rates of new infection with blood-transmitted diseases in Bulgarian 
haemophilic patients is experiencing a steady decline thanks to the introduction of 
recombinant Factor VIII, IX and VIIa preparations in routine practice.  
It is, however, a common concern of families of patients with haemophilia that the 
replacement treatment may bring about adverse events associated with transmission of 
infectious agents, which may lead to adverse health practices. This might be especially true 
for parents with young, newly diagnosed children who are not yet acquainted with the risks 
of spontaneous bleeding and/or the long-term effects of untreated haemophilia on joints, 
internal organs and the brain, and also for parents who are in denial. Such parents may 
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choose not to treat their child or may revert to alternative treatments, believing that the 
consequences of blood-transmitted diseases might be graver than the consequences of 
repeated bleedings. Typically, however, refusal of replacement treatment by the parents is 
not associated with parental neglect but, rather, with overprotectiveness, the behaviour 
stemming from from the erroneous belief that if parents are watchful enough so as not to 
allow physical trauma of the child, bleeding would not occur. Also, there might be 
significant parental opposition to the idea of using recombinant coagulation factor 
preparations out of fear that this might actually increase the risk of antibody production. 
It is vital that the attending clinician together with the genetic counselor review all the 
therapeutic options with the family and and provide reliable information about the rates 
of infection with blood-transmissive agents when using different coagulation factor 
preparations. Misconceptions related to the idea that the replacement could actually make 
the child more ill should be carefully addressed and any associated practices should be 
actively discouraged.  
3. Conclusion  
You have to make the good out of the bad  
because that is all you have got to make it out of.  
Robert Penn Warren, All King’s Men (1946) 
 
Haemophilias produce a heterogeneous phenotype which may be modulated by a number 
of factors, endogenous or resulting from outside intervention. There is a significant inter-
patient variety of disease phenotype even in related patients due to the fact that the clinical 
severity is not always correlated with the residual level of the clotting factor. Genetic 
counselling for haemophilia is a continuous process which aims at gathering maximal 
amount of genetic information pertaining to the nature of genetic mutation causing the 
disease in the particular family, the carriership of additional genetic variants that might 
modulate the phenotype and the potential risks associated with specific traits in the 
patient’s genetic background. In genetic counselling, the patients, their families, the 
attending clinicians, the genetic counselling unit and the clinical laboratory specialists ought 
to work as a team in order to obtain and process information related to the genetic and 
immunological status of the patient and to come up with a management strategy tailored 
out specifically to the needs of the patient. Careful weighing of the risks is important when 
presenting the facts about the familial disease and needless adverse psychological impact 
related to the grave diagnosis and the risks of further transmission of the disease should be 
minimized.  
The genetic counseling unit should be able to provide answers to the vital questions of the 
family associated with the well-being of the affected child/ren and the opportunities for 
family planning. Dealing with popular misconceptions such as the notion that having had 
one affected son  means automatically that the mother is a carrier and the erroneous belief 
that haemophilia could be eventually outgrown must also be on the to-do list of the genetic 
counseling unit as the information they present could provide a convincing proof that the 
disease transmission is governed by strict rules and tends to have a chronic course. It is only 
through dialogue that the best possible outcome for the patient and for the family is 
attained; therefore the process of genetic counseling should include asking a lot of questions 
and giving a lot of answers in order to achieve the optimal results.  
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